Title |
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
|
---|---|
Published in |
BMC Neurology, April 2014
|
DOI | 10.1186/1471-2377-14-79 |
Pubmed ID | |
Authors |
Andrew Siderowf, Michael J Pontecorvo, Holly A Shill, Mark A Mintun, Anupa Arora, Abhinay D Joshi, Ming Lu, Charles H Adler, Douglas Galasko, Carolyn Liebsack, Daniel M Skovronsky, Marwan N Sabbagh |
Abstract |
Biomarkers based on the underlying pathology of Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB) have the potential to improve diagnosis and understanding of the substrate for cognitive impairment in these disorders. The objective of this study was to compare the patterns of amyloid and dopamine PET imaging in patients with AD, DLB and Parkinson's disease (PD) using the amyloid imaging agent florbetapir F 18 and 18F-AV-133 (florbenazine), a marker for vesicular monamine type 2 transporters (VMAT2). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 1% |
Austria | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 75 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 15% |
Researcher | 11 | 14% |
Student > Master | 9 | 12% |
Other | 7 | 9% |
Student > Postgraduate | 6 | 8% |
Other | 13 | 17% |
Unknown | 20 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 20 | 26% |
Neuroscience | 8 | 10% |
Psychology | 6 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Nursing and Health Professions | 2 | 3% |
Other | 8 | 10% |
Unknown | 32 | 41% |